GRAIL, Inc.

GRAL

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors Perceptive Advisors RA Capital Management

Catalysts

No catalysts tracked.

Activist Filings

SC 13GBaker Bros. Advisors5.3%Feb 17, 2026

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 2,085,333Value: $178.5M

## Signal Note: Baker Bros. Initiates Massive Position in GRAIL (GRAL) The reported position value of ~$178.5 billion is almost certainly a data error (likely reflecting a filing quirk or price miscalculation), but the underlying signal — Baker Bros. initiating a new 2.09M share stake in GRAIL — is noteworthy. GRAIL's core asset is Galleri, a multi-cancer early detection (MCED) blood test capable of screening for 50+ cancer types, with the company pursuing an FDA PMA submission and awaiting a potential Medicare coverage decision, both of which represent major binary catalysts. Baker Bros. running an extremely concentrated book and opening a new position in GRAIL suggests high conviction around the regulatory/reimbursement pathway for Galleri, likely timed ahead of expected FDA and CMS milestones — investors should verify the dollar value but

Perceptive AdvisorsNEW

More GRAL Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

BCRX3 funds SION3 funds CTNM3 funds IRON3 funds EWTX3 funds SYRE3 funds RYTM3 funds NUVL

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Perceptive Advisors Initiates GRAIL Position Edelman's $20.3M entry into GRAIL suggests confidence in the company's multi-cancer early detection platform, likely ahead of near-term clinical or commercial catalysts (Galleri blood test expansion, reimbursement decisions, or partnership announcements). Perceptive's strong clinical-stage track record indicates conviction in GRAIL's technology differentiation versus competitors in the liquid biopsy space, though the company faces execution risk on clinical validation and payer adoption.